Progress in CAR-T Cell Therapy for Myeloma: What Does the Future Hold?

Published on

Topics include: Treatments

At a recent town meeting  in Atlanta, an audience member asks, “will CAR-T cell therapy be available to multiple myeloma patients in the near future and, if so, who is a good candidate?” Myeloma expert Dr. Rafael Fonseca, from the Mayo Clinic in Arizona, responds by explaining where research is today for the innovative immunotherapy, the goals of clinical trial studies, and CAR-T cell therapy’s potential as a curative strategy for myeloma patients. Watch now to find out more.

This town meeting is sponsored by Amgen, Janssen Pharmaceuticals and Adaptive Biotechnologies. It is produced by Patient Power in partnership with Winship Cancer Institute of Emory University.

View more programs featuring and

Produced in association with Winship Cancer Institute

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Jack Aiello:

I desperately think they are needed.  I hope that as we get them and as we start using them we'll get better about understanding the toxicities and how to manage them and when to use them.  In theory, they could potentially be done even in a larger population than the transplanted cell, but there might be a situation where someone is very sick with other conditions, with a heart condition or a pulmonary condition, where it may not be necessarily the safest thing. 

But I think people are going to try to push the envelope with this, because as they are being used right now it's more of a rescue strategy.  Now, stay tuned.  It may be that five years from now CAR-T cells are part of the up-front therapy, maybe even instead of the stem cell transplant.  

I think there are some patients that will be cured from this.  The reality is some patients that go through stem cell transplant right now, it's a small minority, but there are patients who go through stem cell transplant, who we see in our clinics and are 15 and 20 and 25 years later and still doing very well.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

Dan's Story: My Experience With CAR T-Cell Therapy

Following several unsuccessful rounds of treatment for B-cell non-Hodgkin lymphoma, Dan was told that he only had a few months to live. Hear his experience on a CAR T-cell therapy clinical trial.

Published:

What Are the Potential Side Effects of CAR T-Cell Therapy?

CLL experts, Dr. Nicole Lamanna and Dr. Michael Keating, discuss the risks involved with the new immunotherapy, CAR T-cell therapy. Tune in for a better understanding of the innovative treatment to help you make informed medical decisions.

Published:

Cherie Rineker: Post-CAR T-Cell Trial for Multiple Myeloma

Myeloma patient Cherie Rineker gives Patient Power an inside look into her experience with a CAR T-cell clinical trial. Watch to learn her highs and lows of the trial.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on January 17, 2019